Safeheal SAS raised €35 million (US$39.72 million) in an oversubscribed series C financing round for its temporary ...

Nuevocor Pte. Ltd. has closed a $45 million series B, enabling it to move lead gene therapy NVC-001 into the clinic in the treatment of an inherited form of cardiomyopathy.